A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Rutgers, The State University of New Jersey
Canadian Cancer Trials Group
University of California, San Francisco
Northwestern University
Valerio Therapeutics
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Galectin Therapeutics Inc.